Related Experiment Video
Updated: Jun 15, 2025
Author Spotlight: Balancing Speed, Cost, and Accuracy in Neutrophil Function Assessment with NeutroFun Screen Protocol
Published on: February 9, 2024
Evaluation of neutrophil activation marker in patients with vitiligo
Hala M El-Sadek1, Asmaa A Elmadbouly2, Basma E M Risha3
1Department of Dermatology, Faculty of Medicine for Girls, Al-Azhar University, Cairo, Egypt. HalaMohammed.5323@azhar.edu.eg.
Background:
Vitiligo is an inflammatory, autoimmune disorder. Its pathogenesis is unclear. A neutrophil activation marker (calprotectin) is a protein complex present in many different types of cells and may be used as an indicator of inflammation.
Aims:
This study is to assess calprotectin levels in non-segmental vitiligo patients and compare them to the severity of the illness to identify potential associations.
Methods:
The present inquiry was conducted on thirty non-segmental vitiligo patients and thirty healthy volunteers matched in terms of age and gender. The Vitiligo Area Scoring Index was used to assess the vitiligo severity. Calprotectin levels were measured in serum samples obtained from all participants by Enzyme Linked Immunosorbent Assay.
Results:
Compared to controls, non-segmental vitiligo patients had considerably elevated serum calprotectin levels. Additionally, calprotectin levels were shown to have a significant positive association with disease severity (r = 0.833, P = 0.000).
Conclusions:
Elevated levels of serum calprotectin in non-segmental vitiligo patients relative to healthy individuals with high sensitivity indicated that it may have a role in the vitiligo pathophysiology and can act as a marker for disease monitoring.
